We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Rapid COVID-19 Breath Test Could Evaluate Efficacy of Coronavirus Vaccines

By LabMedica International staff writers
Posted on 05 Jan 2021
A first of its kind clinical trial in the world will evaluate the ability of a rapid COVID-19 breath test to monitor the antibody levels and type of antibodies developed by the population of subjects getting vaccinated for the coronavirus.

Scentech-Medical Inc. More...
(Tel-Aviv, Israel) has received approval for conducting the new clinical trial from the Shamir Medical Center (Asaf Harofe) Review Board (Helsinki committee). As part of the research, Scentech-Medical will test subjects getting vaccinated to map biomarkers specifically related to antibodies of type IgM and IgG. The test to monitor antibody levels and type (which is being developed concurrently with the rapid breath test for coronavirus detection) will be able to provide a quick indication as to the efficacy of all vaccines available on the market, including the Pfizer-BioNTech vaccine. Moreover, such a test has the potential to indicate the immune system's response to various types of vaccines.

There is a clear need for a diagnostic tool that can provide information regarding the immunity levels and efficacy durations of those immunized. Monitoring antibody levels and type of antibodies is of utmost importance due to the fact that there are multiple coronavirus vaccines available on the market and even more expected to come to market in the near future.

Additionally, Scentech-Medical also continues its ongoing clinical trial for the detection of coronavirus positive subjects at the Shamir Medical Center (Asaf Harofe). As part of the trial, the company is verifying the biomarkers that were mapped after its early clinical trials. Scentech-Medical believes that its breath test technology can detect both symptomatic coronavirus active carriers as well as asymptomatic carriers. The VOX system developed by the company was able to detect differences among various test groups: positive subjects, negative subjects, and negative subjects with antibodies for the coronavirus. The company believes that by using the test it has developed for the analysis and quantification of volatile compounds in breath, it can detect coronavirus patients, active symptomatic, and asymptomatic carriers. It may even give an indication of the body's immune response as reflected by the type and level of antibodies expressed by the body.

Scentech-Medical is also working on completing its global analysis system which combines advanced artificial intelligence and unique algorithms developed by the company. This system is aimed for the rapid and automated analysis of data collected by the company's devices to monitor disease spread, detect new mutations of the coronavirus, and identify new disease outbreaks in real-time on both a local and global level. The development of the global analysis system is expected to enter alpha testing within a month.

Related Links:
Scentech-Medical Inc.


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Collection and Transport System
PurSafe Plus®
New
Urine Chemistry Control
Dropper Urine Chemistry Control
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Colorectal cancer under the microscope (Photo courtesy of Adobe Stock)

Unique Microbial Fingerprint to Improve Diagnosis of Colorectal Cancer

Colorectal cancer is the fourth most common cancer in the UK and the second deadliest. New research has revealed that it carries a unique microbial fingerprint, which could help doctors better understand... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.